Cancer NetworkOriginal article
<![CDATA[Real-World Serplulimab Combo Outcomes Validate ASTRUM-005 Trial in ES-SCLC]]>
Data ReadoutpositiveserplulimabPositive
AI Analysis
Summary
Real-world exploratory data validated ASTRUM-005 trial findings, demonstrating that serplulimab maintenance or continuation beyond initial progression may provide incremental survival benefits in extensive-stage small cell lung cancer.
Clinical Trial Data
NCT ID
Outcome Details
Real-world exploratory data showed serplulimab maintenance or continuation beyond initial progression may yield incremental survival benefits in ES-SCLC, validating ASTRUM-005 trial outcomes
Importance:6/10
Sentiment:
0.70
oncologyES-SCLCimmunotherapyreal-world evidenceserplulimab
Related Companies
Read the original article
Published by Cancer Network on July 22, 2026 2:00 PM